Patents by Inventor Loren D. Walensky

Loren D. Walensky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124529
    Abstract: Disclosed herein are cross-linked peptides useful for interfering with and inhibiting coronavirus infection (e.g., infection by SARS-CoV-2). Also disclosed are methods of treating and/or preventing a coronavirus infection (e.g., COVID-19).
    Type: Application
    Filed: March 4, 2021
    Publication date: April 18, 2024
    Inventors: Loren D. Walensky, Gregory H. Bird
  • Patent number: 11952432
    Abstract: The disclosure relates to cell-permeable stabilized peptide modules and methods of use for e.g., cellular delivery of cargoes.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: April 9, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Rida Mourtada, Henry D. Herce
  • Patent number: 11945846
    Abstract: Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: April 2, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Rida Mourtada
  • Publication number: 20240075099
    Abstract: Methods for assessing the efficacy of internally cross-linked p53 transactivation domain-based inhibitor peptides in the treatment of pediatric cancer and methods of using such peptides to treat pediatric cancer are provided.
    Type: Application
    Filed: May 11, 2023
    Publication date: March 7, 2024
    Inventors: Loren D. Walensky, Kimberly Stegmaier, Ann Morgan Cathcart, Björn Stolte
  • Publication number: 20240002450
    Abstract: This disclosure features structurally-stabilized Ebola virus antiviral peptides. Also disclosed are methods of using such structurally-stabilized peptides in the treatment or prevention of an Ebola virus infection or Ebola virus disease.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 4, 2024
    Inventors: Federico Bernal, Amanda L. Whiting, Loren D. Walensky, Gregory H. Bird
  • Patent number: 11834520
    Abstract: This disclosure features structurally-stabilized and/or cysteine-reactive peptide inhibitors for selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. Also disclosed are methods of using such structurally-stabilized and cysteine-reactive peptides in the treatment of BFL-1- and/or MCL-1-expressing or -dependent cancers or diseases of cellular excess (e.g., autoimmune or inflammatory conditions). Also provided are combination therapies comprising such structurally-stabilized and/or cysteine-reactive peptides and inhibitors of the DNA damage response pathway, such as an ATM kinase inhibitor, ATR kinase inhibitor, CHK1/2 inhibitor, or PARP inhibitor; or an inhibitor of MCL-1, or a selective inhibitor of BCL-2, or an inhibitor of BCL-2/BCL-XL, for the treatment of BFL-1-expressing or -dependent cancers (e.g., AML), BFL-1 and MCL-1-expressing or -dependent cancers, or diseases of cellular excess (e.g., autoimmune or inflammatory conditions).
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: December 5, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Gregory H. Bird, Rachel Guerra, Edward Harvey
  • Publication number: 20230330238
    Abstract: The present application describes chimeras which target and degrade essential viral proteins or host proteins involved in viral pathogenesis. In particular, the chimeras of this application combine a moiety that binds to a target protein (such as a coronaviral papain-like protease (PLpro), main protease (Mpro), or other non-structural proteins (e.g., NSP9 or NSP12); or a host protein, such as bromodomain 2, bromodomain 3, or bromodomain 4)), with a moiety that recruits a protein degrader, thereby degrading the target protein. In some instances, the chimera simultaneously induces p53, which itself has anti-viral activity, by engaging HDM2 as the protein degrader. The disclosure also relates to methods of using such chimeras in the prevention and treatment of viral infections, particularly viral infections (such as COVID-19) caused by coronaviruses (such as SARS-CoV-2).
    Type: Application
    Filed: October 14, 2021
    Publication date: October 19, 2023
    Inventors: Henry D. Herce, Loren D. Walensky
  • Publication number: 20230228759
    Abstract: This disclosure relates to the surprising and unexpected finding that the well-known cancer protein, Myeloid Cell Leukemia-1 (MCL-1), binds to and modulates the enzymatic activity of Very Long Chain Acyl CoA Dehydrogenase (VLCAD), thereby regulating fatty acid ?-oxidation. This finding is employed in compositions and methods of treating cancer, metabolic diseases, or other conditions characterized by excessive fatty acid ?-oxidation by blocking or reducing the energy production of cells (e.g., cancer) through inhibiting the MCL-1/VLCAD interaction and/or directly inhibiting VLCAD enzymatic activity. In addition, the disclosure features methods for identifying such agents that inhibit the interaction between MCL-1 and VLCAD or that inhibit VLCAD enzymatic activity.
    Type: Application
    Filed: November 29, 2022
    Publication date: July 20, 2023
    Inventors: Loren D. Walensky, Silvia Escudero
  • Publication number: 20230192789
    Abstract: Disclosed herein are peptides and structurally-stabilized peptides that selectively bind to HDMX, or both HDMX and HDM2 as well as compositions comprising the same. Also provided are methods for using such peptides in the treatment and diagnosis of cancer (e.g., HDMX-expressing and/or -dependent cancers).
    Type: Application
    Filed: April 27, 2021
    Publication date: June 22, 2023
    Inventors: Loren D. Walensky, Yael Ben-Nun, Henry D. Herce
  • Publication number: 20230183309
    Abstract: This disclosure features structurally-stabilized peptides that target glucagon-like peptide 1 receptor (GLP-1R), compositions comprising same, and methods for using such peptides in the treatment of diabetes, hyperglycemia, cardiovascular disease, obesity, Alzheimer’s disease, Huntington’s disease, and other conditions that can benefit from increased GLP-1 agonist activity and in increasing cAMP levels
    Type: Application
    Filed: December 18, 2020
    Publication date: June 15, 2023
    Inventors: Loren D. Walensky, Gregory H. Bird
  • Publication number: 20230132372
    Abstract: In some embodiments, a mass spectrometry tag may comprise a linker region, a mass balance region, and a reporter region. The mass spectrometry tag may be configured to fragment in a mass spectrometer via an energy dependent process to produce multiple reporter molecules. For example, the reporter region of the tag may be configured to produce at least two reporter molecules via fragmentation. In some embodiments, one or more regions of the tag may comprise at least one heavy isotope. In some such embodiments, the ability to fragment into multiple reporter molecules as well as the placement and/or number of heavy isotope(s) allows the mass spectrometry tag to be distinguished from other similar mass spectrometry tags. In some such embodiments, the ability to distinguish between tags having the same or substantially similar total mass to charge ratio and reporter region mass may allow the system to have a greater multiplexing capacity than conventional systems.
    Type: Application
    Filed: July 28, 2021
    Publication date: April 27, 2023
    Applicants: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Craig Braun, Wilhelm Haas, Steven P. Gygi, Gregory H. Bird, Loren D. Walensky, Martin Helmut Wuhr, Brian K. Erickson
  • Publication number: 20230116760
    Abstract: This disclosure features structurally-stabilized oncolytic peptides and related compositions and methods of making same. Also disclosed are methods of using such structurally-stabilized peptides in the treatment of cancer, e.g., a hematological cancer, e.g., a leukemia, a lymphoma, or multiple myeloma, and/or in the inhibition of proliferation of a cancer cell, e.g., a hematological cancer, e.g., a leukemia and/or a lymphoma and/or a multiple myeloma cell. Also disclosed are methods of using such structurally-stabilized peptides for killing cancer cells or dual-killing cancer cell and micro-organisms, and thus providing therapeutics to treat cancer with or without simultaneously preventing or treating infection, while avoiding toxicity to normal, non-cancerous cells.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 13, 2023
    Inventors: Loren D. Walensky, Rida Mourtada, Henry D. Herce
  • Publication number: 20230077821
    Abstract: Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.
    Type: Application
    Filed: August 29, 2022
    Publication date: March 16, 2023
    Inventors: Rosalind Segal, Loren D. Walensky, Lisa V. Goodrich, Sarah Elizabeth Raissi, Maria F. Murphy, Gregory H. Bird
  • Patent number: 11567082
    Abstract: This disclosure relates to the surprising and unexpected finding that the well-known cancer protein, Myeloid Cell Leukemia-1 (MCL-1), binds to and modulates the enzymatic activity of Very Long Chain Acyl CoA Dehydrogenase (VLCAD), thereby regulating fatty acid ?-oxidation. This finding is employed in compositions and methods of treating cancer, metabolic diseases, or other conditions characterized by excessive fatty acid ?-oxidation by blocking or reducing the energy production of cells (e.g., cancer) through inhibiting the MCL-1/VLCAD interaction and/or directly inhibiting VLCAD enzymatic activity. In addition, the disclosure features methods for identifying such agents that inhibit the interaction between MCL-1 and VLCAD or that inhibit VLCAD enzymatic activity.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: January 31, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Silvia Escudero
  • Patent number: 11466064
    Abstract: Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: October 11, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Rosalind Segal, Loren D. Walensky, Lisa Vaughn Goodrich, Sarah Elizabeth Raissi, Maria F. Murphy, Gregory H. Bird
  • Publication number: 20220298154
    Abstract: This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells).
    Type: Application
    Filed: May 27, 2022
    Publication date: September 22, 2022
    Inventors: Loren D. Walensky, Evripidis Gavathiotis
  • Publication number: 20220213146
    Abstract: Provided herein is a platform technology for designing stabilized peptides that covalently bind their target protein and thereby inhibit the activity of the target protein. Also provided are exemplary stabilized peptides that can be used for covalent modification of their target proteins.
    Type: Application
    Filed: July 30, 2021
    Publication date: July 7, 2022
    Inventors: Loren D. Walensky, Gregory H. Bird
  • Publication number: 20220204572
    Abstract: The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to ?-catenin in vitro, in cellulo, and in vivo, disrupting the BCL9/?-catenin interaction, and thereby interfering with deregulated Wnt/?-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 30, 2022
    Inventors: Loren D. Walensky, Ruben Carrasco, Gregory H. Bird
  • Patent number: 11358960
    Abstract: This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells).
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: June 14, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Evripidis Gavathiotis
  • Publication number: 20220169688
    Abstract: This disclosure features structurally-stabilized and/or warhead-bearing structurally stabilized peptide inhibitors for targeting ubiquitin activating enzymes (E1). Also disclosed are methods of using such structurally-stabilized and warhead-bearing structurally stabilized peptides in the treatment of E1-expressing or -dependent cancers or diseases. Also provided are combination therapies N comprising such structurally-stabilized and/or warhead-bearing structurally stabilized peptide for the treatment of E1-expressing or -dependent diseases.
    Type: Application
    Filed: April 17, 2020
    Publication date: June 2, 2022
    Inventors: Loren D. Walensky, Ann Morgan Cathcart, Gregory H. Bird